2007 BIO International Convention, the Global Event for Biotechnology, takes place May 06 - 09, 2007 at the Boston Convention & Exhibition Center. For in-depth information about the event, visit http://www.bio2007.org/Media/releases.html.
Below are profiles from BIO exhibitors, listed M through Z.
Business Wire is the official news wire for 2007 BIO International Convention. Breaking news releases and photos are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource as well as the official show site.
| Company: | Maxiom Group |
| Booth: | Booth 533/Pod D12 |
| Media Contact: | Jennifer Fiorentino |
| Phone: | 781-239-1030 |
| E-mail: | jfiorentino@parnold.com |
| Web: | www.maxiomgroup.com |
| Maxiom Group is a leading strategic business and IT consulting firm exclusively serving the life sciences industry. Located in Waltham, Massachusetts, Maxiom Group specializes in transforming emerging, established, and mature biotechnology, pharmaceutical, and medical device companies at each stage of their life cycle by solving mission critical business issues. From drug discovery and development, to clinical trials, to commercial launch and sustained market leadership, Maxiom Group clients rely on our unique focus, insight and approach. For more information please visit www.maxiomgroup.com. | |
| Company: | MEDICEN PARIS REGION |
| Booth: | 1307 |
| Media Contact: | Isabelle Boyer de la Giroday |
| Phone: | 33 1 44 49 30 00 |
| E-mail: | igiroday@medicen.org |
| Web: | www.medicen.org |
| Medicen Paris Region unites all the key life science and healthcare players in the Paris metropolitan area. Located at the heart of Europe's leading regional economy, the cluster brings together the highest concentration of healthcare expertise and resources in Europe. | |
| This ambition is shared by major pharmaceutical and healthcare companies, biotech & medtech entrepreneurs, public and private research organizations, Europe's leading hospital network and the region's universities and Grandes Écoles. | |
| These stakeholders are developing close partnerships and active collaborations around innovative projects, company start-ups and business creation. For additional information email contact@medicen.org. | |
| Company: | MedMira Laboratories Inc. |
| Booth: | 807 - Atlantic Canada Pavilion |
| Ticker Symbol & Exchange: | MIR TSX Venture exchange |
| Media Contact: | Dr. James Smith - VP - Corporate Affairs and Human Resources |
| Phone: | 902 450 1588 |
| E-mail: | ir@medmira.com |
| Web: | www.medmira.com |
| MedMira's focus is helping people know"¦®. We do this by bringing quality diagnostic solutions closer to end-users - laboratory professionals, healthcare providers and individuals. | |
| In a world continually faced with overwhelming healthcare epidemics and challenges, healthcare providers, researchers, governments and businesses are not standing still and neither is MedMira. We have a robust line of rapid diagnostics for today's healthcare challenges. The tools we provide can help control and prevent the HIV and Hepatitis C epidemics from reaching future generations. Today, HIV and Hepatitis C are two of the top 10 causes of infectious disease deaths worldwide. | |
| MedMira is developing revolutionary solutions to prevent tomorrow's epidemics. As we continue to build on our line of rapid diagnostics, we are expanding our focus to confirmatory testing, offering customers an end-to-end diagnostic solution. Through our Maple Biosciences division, we are en route to changing the face of laboratory diagnostics with biosensor technologies, which will make the routine laboratory tests of today obsolete, improving both the delivery of healthcare and the patient experience. | |
| Company: | Meissner Filtration Products, Inc. |
| Booth: | 2469 |
| Media Contact: | Karisa Koenig |
| Phone: | 805-388-9911 |
| E-mail: | karisak@meissner.com |
| Web: | www.meissner.com |
| From clinical trials through full-scale production, Meissner offers leading filtration solutions for your process. Meissner Technical Services (MTS) provides complete validation services, documentation & customer support to select/size/install/maximize filtration systems. Membrane filters (0.04-1.0 µm absolute) include SteriLUX® PVDF, STyLUX® and EverLUX PES, Chemdyne® Polypropylene (PP) and Ultradyne® PTFE. Microfiber prefilters in ALpHA® PP, Protec RF borosilicate glass and Protec RM dual-layer glass/PVDF membrane & DeltaMax/DeltaDepth PP depth filters are offered. Configurations include syringe filters, discs, capsules, high-capacity UltraCap®/UltraCap® H.D. (Heavy Duty) capsules, cartridges & DPS (Disposable Processing System) filter/bio-container assemblies. | |
| Company: | MetaMorphix, Inc. |
| Booth: | #490 - Maryland Pavilion |
| Media Contact: | Theresa Brady |
| Phone: | 301.575.2505 C: 410.533.6328 |
| E-mail: | tbrady@metamorphixinc.com |
| Web: | www.metamorphixinc.com |
| MetaMorphix is a leader in providing DNA analytical services to canine registry organizations. These services include parentage testing and pedigree certification. MMI Genomics, a wholly-owned subsidiary of MetaMorphix, Inc., is the principal DNA analytical service provider for the AKC and the UKC, the two largest breed registrations in the United States. | |
| The Canine Heritage Breed Test is the most recent product to come from MMI's exclusive, state-of-the-art, SNP-based DNA technology. The test genetically identifies the composition of mixed breed dogs. Currently the test can identify 38 major breeds which make up approximately 75% of the domestic canine purebred population. | |
| Company: | Missouri Biotechnology Association (MOBIO) and Missouri Department of Economic Development |
| Booth: | 2145 |
| Media Contact: | Cheri Winchester |
| Phone: | 636-262-8313 |
| E-mail: | cwinchester@commongroundpr.com |
| Web: | www.mobio.org |
| From earning constitutional protection for stem cell research to converting tobacco plants into cancer-fighting drugs, Missouri has proven to be more than a fly-over state for biotechnology research. | |
| For reporters interested in covering the latest agriculture and human health advances courtesy of biotechnology research, we can connect them with the people and organizations behind the breakthrough science, addressing timely issues from biodiesel to the latest plant biotech traits and stem cell research. Also learn why global biotech institutions are investing several hundred million dollars in current construction of new bioscience capital investments in Missouri. | |
| Company: | MMG |
| Booth: | 600 |
| Media Contact: | Whitney Brimfield |
| Phone: | 301-984-7191 |
| E-mail: | mmg@mmgct.com |
| Web: | www.wegetpatients.com |
| At MMG, we focus on the best ways to identify sites and reach patients for your clinical trials. During our 20-year history we've brought together some of the nation's leading experts in clinical trial recruitment and retention. Nobody understands patients, their healthcare providers, and how to reach them like MMG. | |
| Company: | MPI Research |
| Booth: | 2273 |
| Media Contact: | Peggy Foster |
| Phone: | 269-668-3336 ext. 1817 |
| E-mail: | Peggy.foster@mpiresearch.com |
| Web: | www.mpiresearch.com |
| MPI Research is a full service Contract Research Organization that serves the biotech and the pharmaceutical industries in meeting their nonclinical and early clinical drug development research needs, from discovery to regulatory submission. Known for our state-of-the-art facilities, excellent study quality, regulatory experience, AAALAC accreditation, and GLP compliance, we partner with our Sponsors in delivering on time, high quality, innovative and cost-effective solutions. From single study protocols to multiple projects across our broad scope of services, we have the capacity and resources to start your studies promptly so that you can achieve your project milestones. For complete information, visit our website at www.mpiresearch.com. | |
| Company: | MSOURCE |
| Booth: | Belgian Pavilion/Flanders BIO |
| Media Contact: | Adriaan Hart de Ruyter |
| Phone: | 32 2 768 01 66 |
| E-mail: | info@msource-cro.com |
| Web: | www.msource-cro.com |
| MSOURCE offers Clinical Insourcing & Outsourcing services across Europe: | |
| "¢Clinical Contract Hire | |
| --Temporary staffing of qualified clinical research employees working under MSOURCE contract | |
| "¢Clinical Trial Management | |
| --Phase I to IV clinical trials | |
| --From Study design till Final Study report | |
| "¢Clinical Data Management and Biostatistical Services | |
| --Clinical Data Management for development and late phase trials | |
| --Biostatistics and SAS programming | |
| --Medical Writing | |
| "¢Quality Assurance & Regulatory Consulting | |
| --Consultants, trainers and auditors with strong clinical background. | |
| "¢Pharmacovigilance and Medical Affairs | |
| --EU CTD Compliant handling/reporting of SAE's | |
| --Medical/Scientific consulting | |
| Company: | Multiple Myeloma Research Foundation |
| Booth: | 3221 |
| Media Contact: | Anne Quinn Young |
| Phone: | 203-652-0212 |
| E-mail: | Quinnyounga@themmrf.org |
| Web: | www.multiplemyeloma.org |
| The mission of the MMRF is to invest urgently and aggressively in research that will get treatments to patients as fast as possible and ultimately find a cure for myeloma. | |
| The MMRF supports one of the scientific community's most innovative and responsive research grant programs. They are the #1 private funder of myeloma-specific research worldwide, and will disseminate $11 million in funding in 2007. Visit www.multiplemyeloma.org to learn more. | |
| Company: | Murphy & McManus, LLC |
| Booth: | 533 |
| Media Contact: | Robert Murphy |
| Phone: | 781-444-3510 |
| E-mail: | rmurphy@murphymcmanus.com |
| Web: | www.murphymcmanus.com |
| For more than 17 years, Murphy & McManus has assisted clients in managing major capital projects to ensure budget, schedule, and performance objectives are achieved and exceeded. Murphy & McManus is a qualified Project Management firm with a staff of expert financial, architectural, engineering, and construction professionals that provide a multi-disciplined approach to executing a project. We have developed a set of systems and controls to provide accurate and effective planning, estimating, forecasting, and scheduling. Our systems and expert advice enable our clients to make timely and informed project decisions that are critical in the ultimate success on a project. | |
| Company: | National Jewish Medical and Research Center |
| Booth: | Colorado Pavilion #1483 |
| Media Contact: | William Allstetter |
| Phone: | (303)398-1002 |
| E-mail: | allstetterw@njc.org |
| Web: | http://www.nationaljewish.org |
| National Jewish, a private, nonprofit institution, and the #1 respiratory hospital in the US, conducts groundbreaking clinical and scientific research in the fields of respiratory and allergic diseases, inflammation, and immunology. National Jewish has close to 150 technologies in its active portfolio and owns 55 active issued U.S. patents plus additional corresponding foreign patents. National Jewish ranks in the top 5% of NIH funded institutions in terms of dollars received every year and two HHMI-funded investigators are part of our faculty. We actively seek commercial partners to complement our clinical trial, research, & technology transfer programs. | |
| Company: | NeuroHealing Pharmaceuticals, Inc. |
| Media Contact: | Daniel Katzman |
| Phone: | 617 331-4111 |
| E-mail: | Daniel@neurohealing.com |
| Web: | www.neurohealing.com |
| NeuroHealing is developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system. Clinical stage programs include: NH001 (phase II), a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative or minimally consciousness state; NH004 (phase II), an anticholinergic agent in a convenient intra-orally muco-adhesive dissolving film to help treat Parkinson's and other motor neuron disease patients who suffer from sialorrhea (drooling); and NH02D, a novel mechanism compound to accelerate the rehabilitation outcomes of stroke patients who remain with chronic motor and cognitive disabilities. | |
| Company: | Nevada Development Authority |
| Booth: | 1807 |
| Media Contact: | Riley Meredith, riley@preferredpublicrelations.com, (702) 254-5704 |
| Phone: | 888-4-NO-TAXES |
| E-mail: | info@nevadadevelopment.org |
| Web: | www.nevadadevelopment.org |
| The mission of Nevada Development Authority (NDA) is to attract, retain and expand the business base and enhance the overall socioeconomic environment of Southern Nevada. Established in Las Vegas in 1956, NDA is Southern Nevada's largest economic development agency and contributes to the area's prosperity by attracting new companies and assisting local companies in expansion projects. | |
| The Nevada Development Authority has successfully recruited more than 60 businesses to Las Vegas this past fiscal year, including high tech, communications and life science companies. Currently, NDA is implementing a campaign to recruit bio tech and life science businesses on the east coast. | |
| Company: | New Jersey Research Universities |
| Booth: | 1122 |
| Media Contact: | Judith Sheft |
| Phone: | 973-596-5825 |
| E-mail: | sheft@njit.edu |
| Web: | www.njit.edu / www.rutgers.edu / www.princeton.edu / www.umdnj.edu |
| New Jersey offers a rich academic environment, housing prestigious colleges and universities and advanced technology development centers. New Jersey Institute of Technology, Princeton University, Rutgers University, the state university of New Jersey and University of Medicine and Dentistry of New Jersey comprise core components of the state's academic research and technology development infrastructure. These universities deliver advances in complementary areas of scientific discovery in the public interest. Successful public/private/academic collaborations have helped support the growth of the state's position as a leader in health care. Areas of key expertise include work in biomedical engineering, neuroscience, nanotechnology, stem cell research, and pharmaceutical engineering. | |
| Company: | Next Generation Clinical Research |
| Booth: | 1145 - Wisconsin Pavilion |
| Media Contact: | Matthew Hanson |
| Phone: | 608-835-5811 |
| E-mail: | mhanson@nextgenclinical.com |
| Web: | www.nextgenclinical.com |
| Next Generation is a Contract Research Organization (CRO) that provides clinical trial management, monitoring, data management, regulatory affairs and management services to small and mid-sized pharmaceutical and biotechnology organizations. Our specialties include complex projects and trial designs or unique delivery methods in multiple therapeutic areas. We command particular expertise in Nephrology, Bone Disease, Dermatology and Central Nervous System disorders. | |
| Company: | NH, State of & Public Service of NH |
| Booth: | 2133. |
| Media Contact: | John R. DiNapoli, Business Development Manager |
| Phone: | 603-271-2591 X 114 |
| E-mail: | jrdinapoli@dred.state.nh.us |
| Web: | www.nheconomy.com |
| NH, State of and Public Service of NH work together in attracting businesses to NH. Our organizations, along with others (business, government and education) assist companies in creating jobs. Contact our offices for additional details on how your company can benefit by locating/expanding to NH today at (603) 271-1591 or 634-2386 www.nheconomy.com or www.psnh.com | |
| Company: | NHS Innovations London |
| Booth: | 1864 |
| Media Contact: | Laura James |
| Phone: | 44 (0)207 380 1711 |
| E-mail: | laura.james@nhsinnovationslondon.com |
| Web: | www.nhsinnovationslondon.com |
| The NHS is the UK's main healthcare provider and its biggest employer of science graduates. It is the 3rd largest organisation in the world and is the biggest recruiter in Europe. As a service with technology at its forefront the NHS is a significant source of healthcare innovations. These innovations fulfill real needs, originating from the day-to-day provision of healthcare. | |
| NHS Innovations London identifies, protects and commercialises the ideas and research of over 65 NHS Hospital Trusts in London including hospitals specialising in cancer, cardiology, heart & lung disease, pediatrics, psychiatric medicine, acute & trauma services and neurosciences with many having world class research facilities and laboratories. NHSIL manages innovations competitions and undertakes IP audits to identify potential inventions. The assessment and development of these technologies is crucial to their success and our best practice evaluation, protection, development and commercialisation process results in a pipeline of technologies with decreased risk and increased value. | |
| Innovations from the NHS span the healthcare industry and include Therapeutics, Diagnostics, Informatics, Medical Devices, Assistive Technologies, Equipment and Surgery | |
| Company: | NicOx |
| Ticker Symbol & Exchange: | Bloomberg ticker: COX:FP / Reuters ticker: NCOX.PA (EuroNext) |
| Media Contact: | Irene Lalande |
| Phone: | 33 (0)4 97 24 53 11 |
| E-mail: | lalande@nicox.com |
| Web: | http://www.nicox.com |
| NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammatory and cardio-metabolic diseases. Resources are focused on two lead compounds, naproxcinod, in phase 3 development for the treatment of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc. | |
| NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext Paris (segment: Next Economy). | |
| Company: | NPIL Pharma Torcan |
| Booth: | 507 |
| Media Contact: | Nicole Tingley |
| Phone: | 416.904.4735 |
| E-mail: | Nicole.tingley@torcan.com |
| Web: | www.npilpharma.com or www.torcan.com |
| NPIL Pharma is the new global brand in custom manufacturing of RSM, key intermediates, active pharmaceutical ingredients and finished products with operations in India, the UK and Canada. | |
| NPIL creates value across the entire drug development lifecycle by offering integrated services to support preclinical development through to commercialization. | |
| NPIL offers a comprehensive range of chemistry and formulation development services to support preclinical and clinical development. With extensive large-scale assets, including high potency manufacturing, NPIL also offers a flexible, cost-effective commercial pharmaceutical manufacturing services | |
| NPIL Pharma is one of the very few CMO's in the world forward integrated from API/Intermediates development and manufacturing into final dosage forms. | |
| Company: | Norac Pharma |
| Booth: | 1676 |
| Media Contact: | Kirsten Johnson |
| Phone: | 626-812-5538 |
| E-mail: | kjohnson@norac.com |
| Web: | www.noracpharma.com |
| Norac Pharma is a Contract service company who handles outsourcing of API Manufacture, Process Development, and Analytical services. Centrally located in California, we are the ideal partner for local companies seeking to outsource API production. | |
| With almost five decades of experience in manufacturing APIs, and expertise in the production of Controlled Substances and Potent Compounds, Norac Pharma delivers a timely, efficient, and compliant product. | |
| Company: | North Carolina Biotechnology Center |
| Booth: | 1655 |
| Media Contact: | Jim Shamp, News and Publications Editor |
| Phone: | 919-541-9366 |
| E-mail: | Jim_shamp@ncbiotech.org |
| Web: | www.ncbiotech.org |
| The North Carolina Biotechnology Center is a private, non-profit corporation established in 1984 as the world's first government-sponsored biotechnology initiative. Its mission is to provide long-term economic and societal benefits to North Carolina by supporting biotechnology research, business and education statewide. | |
| Headquartered in Research Triangle Park, the Center has five small offices across the state to encourage regional and niche development of biotechnology. The Center is supported by the state's General Assembly and has a budget is $17.6 million and a staff of 65. | |
| North Carolina has the nation's third largest biotechnology industry with 350 bioscience companies employing 48,000 people. Visit www.ncbiotech.org. | |
| Company: | North Carolina Department of Commerce |
| Booth: | Pavilion 1655 |
| Media Contact: | Mira Meghdessian |
| Phone: | 646-351-3510 |
| E-mail: | mira.meghdessian@dc-intl.com |
| Web: | www.nccommerce.com |
| North Carolina: The State of Minds. North Carolina's knowledge-based workforce, combined with a network of support organizations focused on collaboration, offers many strategic advantages for the biotechnology, pharmaceutical, and life science industries. Over 350 bioscience companies employ 48,000 people in the state. And North Carolina provides innovative programs to train and replenish this talent pool. | |
| The North Carolina Community College System, the largest per capita in the nation, provides specialized training through its BioNetwork initiative. The North Carolina Biotechnology Center is the world's first government-sponsored organization dedicated to developing the biotechnology industry. | |
| Learn more at the North Carolina Pavilion (#1655). | |
| Company: | NOTOX B.V. |
| Booth: | 2633 |
| Media Contact: | marketing@notox.nl |
| Phone: | 31736406700 |
| E-mail: | marketing@notox.nl |
| Web: | www.notox.nl |
| NOTOX B.V. is a leading contract research organization, providing full safety, toxicology and consultancy services for the pharmaceutical industry, non-clinical testing, in vitro / in vivo toxicology, kinetics and metabolism studies. | |
| Toxicology research is supported by an extensive (bio-)analytical laboratory facility, method validation and metabolite identification. NOTOX has over 70 scientific and regulatory advisors with many years of experience in the non-clinical development of NCE's and biologicals. Our consultants, scientists and project coordinators, use their knowledge and experience to design complete programs for each specific compound from lead to Phase I clinical trial. NOTOX B.V. is part of a world wide group of autonomous companies providing toxicology research services for the pharmaceutical industry. NOTOX, Dedicated Crystal Clear | |
| Company: | Nucleus Network |
| Booth: | #1515 |
| Media Contact: | Maria Chiam |
| Phone: | 415 606 5839 |
| E-mail: | m.chiam@clinicaltrialsconsulting.com.au |
| Web: | www.nucleusnetwork.com.au |
| Quality driven clinical trials conducted on-time and on-budget in Australia for biotech, pharma and medical device companies. Services include: | |
| "¢Specialised Phase I and early phase capabilities; | |
| "¢24 bed state-of-the-art in-patient facilities for early phase studies with access to diverse patient and volunteer populations; | |
| "¢Continuous cardiac monitoring (telemetry); | |
| "¢Clinical trial consulting services to create a full clinical development plan and regulatory filings for clinical trial approval and marketing authorisation for Australian and international agencies such as TGA, FDA and EMEA; | |
| "¢Commercial sponsorship for international companies without a corporate presence in Australia available. | |
| Company: | NYC Economic Development Corporation - Bioscience Desk |
| Booth: | 1833 |
| Media Contact: | Bill Fair, Managing Director |
| Phone: | 212 312 3836 |
| E-mail: | bfair@nycedc.com |
| Web: | www.nycbiotech.com |
| Mayor Bloomberg has made bioscience a key priority and projects being addressed by NYC's Bioscience Desk include the East River Science Park. New York City unique bioscience assets include: | |
| --Talent - NY metro area has the largest bioscience workforce | |
| --Research - $1.3B in NIH awards and the largest concentration of academic institutions | |
| --Funding - Wall Street access and 125 healthcare venture capital firms | |
| --Lab/Office Space - office, sales and research labs are here. ERSP will feature 1.1 M sf of offices/labs | |
| --More international flights than any US City | |
| --115 bioscience firms recognize the advantage of their NYC location | |
| Company: | NYCOMED |
| Booth: | hospitality suite at Westin Waterfront Hotel (adjacent to Convention-centre) |
| Media Contact: | Morten Faester |
| Phone: | 45 4056 6888 |
| E-mail: | MOR@nycomed.com |
| Web: | www.nycomed.com |
| NYCOMED is the European specialty pharma which recently acquired Altana-Pharma. | |
| NYCOMED is active in licensing-in of mid-stage projects for co-development and European commercialization -- as well as out-licensing a couple of late-stage projects for US-partnering. | |
| The therapeutic focus areas includes: Pain-management, Hospital cardiology, Respiratory, GI, Osteoporosis and Surgery-management. | |
| Amongst the out-licensing opportunities available are the "Instanyl" nasal fentanyl for breakthrough pain. | |
| Company: | Ocimum Biosolutions |
| Booth: | Booth No.# 2500 |
| Media Contact: | Ashwin Sivakumar |
| Phone: | 00 91 40 66627200-04 |
| E-mail: | ashwin.s@ocimumbio.com |
| Web: | http://www.ocimumbio.com |
| Ocimum Biosolutions is a leading integrated life-sciences R&D enabling company providing focused solutions for enabling different steps of the life-sciences process chain. Our strategic presence in USA, Netherlands and India helps us offer cutting edge technologies at competitive market rates. | |
| Our BioMolecules division provides complementary product lines in Microarrays and Oligos using sophisticated proprietary technologies while adhering to strict quality standards. Through our Ocichip technology, we offer one of the widest ranges of catalog arrays and flexible custom arrays with superior probe design. We offer QUTE (Quantitativel Unique Technique Extracted) oligos with stringent quality controls using proprietary purification technology which is in par with HPLC. | |
| Our Bioresearch division with sophisticated world-class facilities offers a variety of analytical research services in the Molecular Biology space ranging from Sequencing services to gene synthesis. | |
| Our BioIT division provides flexible end to end solutions for management and analysis of complex biological data. | |
| Company: | OmniLingua Inc |
| Booth: | 2372 |
| Media Contact: | Tracie Williams |
| Phone: | 319-892-8119 |
| E-mail: | twilliams@omnilingua.com |
| Web: | www.omnilingua.com |
| OmniLingua Inc, as your globalization management partner, will assist you in developing your global presence, reducing your time to market, and minimizing your risk in new markets. Our precise balance of highly skilled industry-specific experts, global technology systems professionals and the power of the OTIS Management System - proven personnel, processes and tools - can be implemented successfully in any cultural environment. We ensure that your globalization management needs are fulfilled accurately and at the lowest cost over the long-term. At OmniLingua our focus is crystal clear - delivering focused globalization management quality, service and technology to achieve your global service needs. | |
| Company: | Oncolytics Biotech Inc. |
| Ticker Symbol & Exchange: | NASDAQ:ONCY, TSX:ONC |
| Media Contact: | Cathy Ward |
| Phone: | 403.670.7370 |
| E-mail: | cathy.ward@oncolytics.ca |
| Web: | www.oncolyticsbiotech.com |
| Oncolytics Biotech Inc. was formed in 1998 to develop its proprietary product, REOLYSIN®, as a potential therapeutic for a wide variety of human cancers. | |
Oncolytics has completed six clinical trials with REOLYSIN® in Canada, the U.K. and the U.S. and is currently conducting or has approval to commence seven Phase I or Phase II REOLYSIN® trials in the U.K. and the U.S. | |
| The current clinical program includes local or systemic delivery of REOLYSIN® as a monotherapy, and local or systemic delivery of REOLYSIN® in combination with radiation or chemotherapy for patients with advanced cancers. | |
| Company: | Onondaga County - Syracuse NY |
| Booth: | 1833 |
| Media Contact: | Greg Hitchin |
| Phone: | 315-435-3770 or 315-427-8583 (at show) |
| E-mail: | ghitchin@ongov.net |
| Web: | www.SyracuseCentral.com |
| Syracuse and Central New York is a great place to do business! Known as a center of innovation since the 19th century, the community maintains the spirit of innovation while transforming itself into a success in the new economy. Two new initiatives, the CNY Biotechnology Research Center and the Center of Excellence for Renewable Energy will help fuel the regions continued success. A highlight of the area is the new 250-acre Life Science business park. Located in a suburban section of Onondaga County, the Park features the seclusion of a rural setting with easy access to housing, shopping, and airport. | |
| Company: | Open Biosystems, Inc. |
| Booth: | Alabama Pavilion/ 1742 |
| Phone: | 256-704-4848 |
| E-mail: | info@openbiosystems.com |
| Web: | www.openbiosystems.com |
| Open Biosystems offers products that span Genomics, RNAi and Antibodies. Building on the rapid sharing model that is at the core of the Human Genome Project, Open Biosystems collaborates with some of the most innovative life science investigators working today. We partner with them to bring to market new products"”they have often pioneered the new resources in their own lab, and we prepare it for widespread use and then provide access to the research community. | |
| We offer the most complete library or genes in the industry. This novel library consists of several full length cDNA and open reading frame collections. | |
| Company: | Optimata |
| Booth: | Israeli Pavilion (3171) |
| Media Contact: | Guy Malchi, CEO |
| Phone: | 972-3-7519226 |
| E-mail: | info@optimata.com |
| Web: | www.optimata.com |
| Optimata is a modeling based biopharma company that develops computerized tools, Virtual Patient engines, for navigating drug development towards better drugs, faster. | |
| Applying biomathematics to develop a predictive bio-simulation software toolkit, this technology provides a comprehensive drug development solution. | |
It thoroughly unfolds drug patient dynamic interactions, enabling drug developers to perform rapid virtual clinical trials and to forecast optimal drug regimen patient population clinical indication match for a given trial end point. | |
| Optimata's Technology Enables | |
| "¢Drug repurposing | |
| "¢Enhanced drug competitive profile | |
| "¢Early "GO/NO-GO" development decisions | |
| "¢Drug safety profile | |
| "¢Optimal dosing schedules | |
| "¢Clinical indication selection/expansion | |
| Company: | OpStat Group Inc. |
| Booth: | 1371 in Connecticut Pavilion |
| Media Contact: | Jim Curry |
| Phone: | 203.431.3905 |
| E-mail: | JimCurry@OpStat.com |
| Web: | www.OpStat.com |
| With 20-years biopharma experience, OpStat has developed models for capacity, performance and cycle time improvement in manufacturing and laboratory operations. OpStat's simulations and methodology analyze alternatives for equipment, inventory and staffing for R&D, clinical trials, tech transfer and commercial production. | |
| Covering the full scope of the supply chain from cell fermentation, formulation, filling, to packaging, the models include all forms of products - including liquids, solids, lyophilized vials and syringes, transdermals and specialized delivery. Detailed processing, decontamination and cleanout rules provide real-world predicted results. | |
| Laboratory models with attribute test profiles may be used for stand-alone planning or integrated into manufacturing flows. | |
| Company: | Orion Corporation |
| Booth: | 2065 Scandinavia Pavilion |
| Ticker Symbol & Exchange: | ORNAV, ORNBV (OMX, Helsinki) |
| Media Contact: | Tuula Laitinen, Communications Manager |
| Phone: | 358 50 966 2136 |
| E-mail: | tuula.laitinen@orion.fi |
| Web: | www.orion.fi |
| Orion Corporation Orion Pharma is competent in R&D to take products from discovery to MA. Therapy areas CNS, CV and HTU. We provide supportive partnership with the early stage projects. We look for strategic partnerships with universities and companies. Our business includes research, manufacturing and marketing, Northern Europe as home territory. | |
| Company: | Otsuka Pharmaceuticals - ODPI Division |
| Booth: | 1884 |
| Media Contact: | Mr. Koji Yoneda, Director, BD |
| Phone: | 81-6-6231-7158 |
| E-mail: | odpiweb@otsuka.jp |
| Web: | http://otsuka-odpi.com |
| Otsuka Pharmaceutical Co., Ltd. has developed a new DPI System (ODPI System) utilizing a unique lyophilizing technique, by which the company has efficiently formulated proteins, peptides, and chemicals and achieved the easy inhalation of these drugs. The ODPI System comprises a freeze-dried formulation with novel excipients, and a unique yet simple manufacturing method, and a compact and easy-to-use inhalation device. Differing from conventional inhalation systems that require prior pulverization of the drug, the ODPI System achieves micronization of the drug substance with the air impact of a single intake of breath, enabling simultaneous micronization and inhalation. | |
| Company: | PAA Laboratories Inc. |
| Booth: | 1181 |
| Media Contact: | Mark Ferreira |
| Phone: | 508-984-5881 |
| E-mail: | USinfo@paa.com |
| Web: | www.paa.com |
| PAA specializes in the manufacture and worldwide distribution of cell culture products for research, development, diagnostic and biopharmaceutical production. The company processes and manufactures animal & human sera, synthetic media, protein-free media, biochemical supplements and reagents, all of which are used as cell nutrients in cell culture technology. PAA is a privately held company with sales in excess of 32M Euros, with manufacturing operations in Europe, North America and Australia, and sell products in over 40 countries world-wide through direct sales and distributors. | |
| Company: | PaleoTechnology International |
| Booth: | 1620 |
| Media Contact: | Bevo Beaven, CTA Integrated Communications |
| Phone: | (303) 665-4200 |
| E-mail: | bevo@ctaintegrated.com |
| Web: | www.ctaintegrated.com |
| PaleoTechnology International is a technology development and commercialization company creating bio-based products and processes that increase the value derived from natural resource environments. This happens through innovative Bio/Chemical Discovery and Bioprocess Development in diverse environments including petroleum extraction sites, extreme environments, and in zones of significant biodiversity. These specialty products and processes represent the highest and best use of resources from these environments, and contribute to solving global problems associated with existing technologies. | |
| PaleoTechnology, in partnership with the Box Hill Institute in Melbourne, Australia will collaborate on the development of novel products and bioprocesses derived from diverse natural resource environments. | |
| Company: | Palm Beach Gardens, Florida |
| Booth: | 1073 |
| Media Contact: | Dolores Key |
| Phone: | 561.799.4136 |
| E-mail: | bio@pbgfl.com |
| Web: | www.pbgfl.com |
| With cosmopolitan flair and hometown feel, Palm Beach Gardens is your passport to a superb quality-of-life: average sunny temperature of 78°F; proximity to two international airports; beautiful parks and preserves; pristine area beaches; fine shopping and dining; and home of Scripps Florida. | |
| Located on Florida's east coast, Palm Beach Gardens is the epicenter of a burgeoning business community and is home to many notable corporate headquarters: the newest campus of Bascom Palmer Eye Institute, Anspach Companies, 3i, and TransDermal Technologies, compliment the scientific environment. | |
| The Gardens - your ticket to an environment that nurtures success. | |
| Company: | PAREXEL International Corporation |
| Booth: | 533 |
| Ticker Symbol & Exchange: | NASDAQ Exchange: PRXL |
| Media Contact: | Rebecca Passo, SHIFT Communications |
| Phone: | 617-779-1817 |
| E-mail: | rpasso@shiftcomm.com |
| Web: | www.PAREXEL.com |
| PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. PAREXEL will be sponsoring and exhibiting its range of developmental and commercialization services at the 2007 BIO International Convention in the MBC Massachusetts Pavilion, the largest state pavilion. PAREXEL is a Massachusetts Biotech Council (MBC) member and Massachusetts-based, international company. Visit PAREXEL's Booth #533 to learn about the Company's continuing focus on small/emerging biopharmaceutical companies and view a demonstration of its advanced technologies by PAREXEL's subsidiary, Perceptive Informatics. | |
| Company: | Partnership for Biotechnology Research (PBR) |
| Booth: | AL pavilion |
| Media Contact: | Amanda Wallace |
| Phone: | 256-319-1420 |
| E-mail: | info@alpbr.org |
| Web: | www.alpbr.org |
| The Partnership for Biotechnology Research (PBR), a not-for-profit organization, catalyzes and supports the biotechnology entrepreneurial and educational efforts in Huntsville, Alabama. Through quarterly events, PBR highlights national speakers and local research efforts. Activities focus on developing the current and future biotechnology workforce. Established in 2003, PBR now consists of over 250 people from Greater Huntsville. Members range from biotechnology entrepreneurs and employees, to university students and faculty, to a wide range of service and support providers. Visit www.alpbr.org, PBR's online community, for local press releases, details and photos of PBR's events and activities and local job and resume postings. | |
| Company: | PCI Synthesis |
| Booth: | 533 / A26 |
| Phone: | 978-463-4810 |
| E-mail: | sales@pcisynthesis.com |
| Web: | www.pcisynthesis.com |
| PCI Synthesis is a specialty chemical company that manufactures API's and custom chemicals for pharmaceutical, biotech and medical device companies. PCI offers a full complement of process research, development and manufacturing services from single grams to metric tons. | |
PCI has the proven ability to navigate the regulatory processes with its cGMP manufacturing status and DMF submissions. The company is harmonized to the ICH guidelines and is Part 11 7a compliant. PCI has undergone both general site and pre-approval inspections from the FDA at its manufacturing plant in Newburyport, MA and its research center in Devens, MA facilities. | |
| Company: | Pennsylvania Bio |
| Booth: | Pennsylvania Pavilion - Booth 1440 |
| Media Contact: | Karla White |
| Phone: | 610-578-9220 |
| E-mail: | karla@pennsylvaniabio.org |
| Web: | www.pennsylvaniabio.org |
| Pennsylvania Bio is the Voice of Advancement for the biosciences community in Pennsylvania, representing the continuum of the industry"”research institutions; emerging biotech, device, and diagnostic companies; global pharmaceuticals; and support organizations. Pennsylvania Bio serves as a point of contact for information on the bioscience industry in Pennsylvania, including industry trends, the industry's impact on the commonwealth's economy, workforce initiatives, and public policy and its impact on the biosciences. | |
| Company: | Pennsylvania Department of Community and Economic Development |
| Booth: | Pennsylvania Pavilion, Booth 1440 |
| Media Contact: | Ted Martin |
| Phone: | 717-720-1388 |
| E-mail: | themartin@state.pa.us |
| Web: | www.newpa.com |
| Pennsylvania is the center of life science innovation "”world-class basic research, emerging companies, mature industry, global pharmaceuticals and support organizations. Our $2 billion Life Sciences Enterprise commitment and $2.8 billion Economic Stimulus program are unrivaled. Make your business investment succeed. Put Pennsylvania in your future. | |
| Pennsylvania Department of Community and Economic Development | |
| Commonwealth Keystone Building | |
| 400 North Street, 4th Floor | |
| Harrisburg, PA 17120 | |
| 800-237-4363 | |
| www.newPA.com | |
| Company: | Pennsylvania State University, The |
| Booth: | 1440 - Pennsylvania Pavilion |
| Media Contact: | Bill Mahon |
| Phone: | 814-863-1028 |
| E-mail: | bmahon@psu.edu |
| Web: | http://www.psu.edu |
| Penn State offers research partnering, training, and educational opportunities in medical devices; drug delivery and discovery; biomaterials; nanobiotechnology; bioinformatics; pharmaceutical and health industry management; and bio-based materials and products for agricultural applications. The Penn State Industrial Research Office (www.iro.psu.edu) is available to assists companies in accessing these opportunities through the Hershey Medical Center, The Huck Institutes of the Life Sciences, Materials Research Institute, and College of Agricultural Sciences. | |
| Company: | PerkinElmer Life and Analytical Sciences |
| Booth: | 2202 |
| Ticker Symbol & Exchange: | NYSE symbol: PKI |
| Media Contact: | Sigrid Tehrani |
| Phone: | 508-241-2697 |
| E-mail: | Sigrid.tehrani@perkinelmer.com |
| Web: | Perkinelmer.com |
| PerkinElmer's OneSource is a business improvement solution that provides the skills and capabilities necessary to enable Scientists to focus on Science. Our one-contact, one-contract solutions lower costs, increase productivity and enhance regulatory compliance. OneSource offers scalable, tailored business solutions for all lab equipment maintenance and asset management activities. Through consolidated and proactive management, OneSource provides customers with better control of their maintenance costs and improves laboratory productivity through increased uptime. For additional information about OneSource, contact PerkinElmer at (781) 663-6900. | |
| Company: | Perkins Coie LLP |
| Booth: | 1266 |
| Media Contact: | Julie Kaplan |
| Phone: | 310.788.3287 |
| E-mail: | JLKaplan@perkinscoie.com |
| Web: | www.perkinscoie.com |
| Perkins Coie serves great companies ranging in size from FORTUNE 100 companies to start-ups. The firm has more than 600 attorneys in 15 offices across the United States and in China and has historically represented market leaders in traditional and cutting-edge technology industries. We employ a multidisciplinary approach to provide a comprehensive range of legal services to life sciences clients at every stage of growth. | |
| Company: | PIERRE FABRE MEDICAMENT Active Ingredients Division |
| Booth: | 1424 |
| Media Contact: | Yann BAYEUX |
| Phone: | 33.563.81.24.00 |
| E-mail: | Yann.bayeux@pierre-fabre.com |
| Web: | www.plantes-industrie |
| PFM - active ingredients division, is focused on new process development, industrialization and commercial production of cGMP APIs. We are active in cytotoxic APIs : vinorelbine, vinflunine, etoposide etc"¦ We are also highly skilled in natural product extraction and purification. We are equipped with continuous extraction chains to extract up to 1t/h of dried plant. The material can then be purified by HPLC (450mm) and some chemical steps can be added. Based on our know-how in SuperCritical Fluids, we have developed a multi-purpose technology platform : Nanoparticles, FORMULPLEX® and FORMULCOAT® used in bioavailability/solubility enhancement, taste masking or micronization. | |
| Company: | Pittsburgh Regional Alliance |
| Booth: | 1440 - Pennsylvania Pavilion |
| Media Contact: | Bernie McShea |
| Phone: | 412-260-6464 |
| E-mail: | bmcshea@pittsburghregion.org |
| Web: | www.pittsburghregion.org |
| The Pittsburgh Regional Alliance is the regional economic development and investment promotion agency for the Pittsburgh, Pennsylvania area. We maintain close relationships with leading life sciences companies in our region such as Medrad, Bayer, Respironics, and Cellomics, and have assisted in locating and expanding them in our region. We are quite knowledgeable about life sciences investment trends in our region, both among private companies as well as world-class research institutions (e.g., University of Pittsburgh, Carnegie-Mellon University). | |
| Company: | PharmaCell |
| Booth: | Netherlands Pavilion #2633 |
| Media Contact: | Maurice M.M. Horsten, VP Marketing & Sales |
| Phone: | 31-43-3509910 |
| E-mail: | m.horsten@pharmacell.nl |
| Web: | www.pharmacell.nl |
| PharmaCell is a Life Science company providing know-how and resources for product an process design combined with GMP manufacturing in its own facility. PharmaCell is located in the Biopartner Center Maastricht and, therefore, can take advantage of an extensive network to mediate in R&D, financing and housing requirements of the clients. Close cooperation with the Maastricht University and the associated Academic Hospital gives PharmaCell the unique capability to provide support and/or partnership to R&D companies to bring new products from the lab into the clinic. | |
| Company: | PLANET LLC |
| Booth: | 1133 |
| Media Contact: | Ms. Marty Gustafson |
| Phone: | 608-827-5555 |
| E-mail: | gustafsonm@hypercosm.com |
| Web: | www.planet-lcc.com |
| PLANET LLC strives to transition technologies from initial development stages to viable commercial markets. Under a strategic alliance with Orbital Technologies Corporation, PLANET LLC has advanced space-based technologies into products for the life sciences, education, space resources, and biomedical markets. Offerings include LED lighting, plant-growth systems, lunar simulant, web-based 3D software and physical rehabilitation. | |
| PLANET LLC is currently focused on the commercialization of controlled environment capabilities into controlled agricultural manufacturing for new products such as medicines, nutraceuticals, and other protein chemistry that utilize plants as key step in production. | |
| Company: | Praxair, Inc. |
| Booth: | 1007 |
| Ticker Symbol & Exchange: | PX (NYSE) |
| Media Contact: | Hope Dipierro |
| Phone: | 203-837-2573 |
| E-mail: | Hope_dipierro@praxair.com |
| Web: | www.praxair.com/biopharma |
| Praxair supports key stages in the lifecycle of biopharma product development, assuring consistent quality, efficiency and reproducibility from discovery to scale-up to production. | |
| Praxair, Inc. is the largest industrial gases company in North and South America, and one of the largest worldwide, with 2006 sales of $8.3 billion. The company produces, sells and distributes atmospheric and process gases, and high-performance surface coatings. Praxair products, services and technologies bring productivity and environmental benefits to a wide variety of industries, including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing, metals and others. More information on Praxair is available at www.praxair.com | |
| Company: | Primorigen Biosciences LLC |
| Booth: | 1139 |
| Media Contact: | Chuck Oehler |
| Phone: | 608-441-8334 |
| E-mail: | info@primorigen.com |
| Web: | www.primorigen.com |
| Primorigen Biosciences LLC is a leader in developing fluorescent, multiplexed immunoassays for detecting protein biomarkers for cell therapy research and other applications. The company offers complete contract capabilities for rapid monoclonal antibody development, custom assays and microarrays, cDNA cloning, protein expression/purification, and automated statistical design of experiment optimization. Partnering interests include match pair antibodies, novel substrates and slides for microarrays, systems for protein quantification and total cell characterization, novel detection systems, and related technologies. Primorigen's scientists come from leadership roles at some of the world's prominent biotechnology companies. The company recently expanded operations at University Research Park in Madison, WI. | |
| Company: | ProNAi Therapeutics, Inc. |
| Media Contact: | Mario Fante, Aviator PR |
| Phone: | 617-763-9887 |
| E-mail: | mario@aviator-pr.com |
| Web: | www.pronai.com |
| ProNAi Therapeutics, Inc. is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is developing multiple DNAi® drug candidates with the potential to treat multiple cancers, including non-Hodgkin's lymphoma, prostate, breast, and colon cancers. The company's lead drug candidate, PNT2258, which has demonstrated in vivo efficacy in a variety of human tumor xenograft models, is currently in preclinical development. ProNAi is also exploring the potential of DNAi® therapies for indications beyond oncology. | |
| Company: | Pronota nv |
| Booth: | Stand 3033, Belgium Pavilion |
| Media Contact: | Sofia Vindevogel |
| Phone: | 32 9 241 11 64 |
| E-mail: | Sofia.vindevogel@pronota.com |
| Web: | www.pronota.com |
| Pronota, the Belgium-based protein biomarker company, is developing a new generation of diagnostic and pharmacodiagnostic products based on protein biomarkers. The Company's advanced technology identifies protein biomarkers in biological samples that provide insight in disease etiology. It can also identify protein biomarkers that distinguish between patients that will and will not respond to certain drugs to determine best treatment options. Pronota also provides contract research services for protein biomarker discovery to pharmaceutical and diagnostic companies. | |
| To find out more about Pronota and its exciting developments in the protein biomarker field, come and talk to Koen Kas, Chief Scientific Officer, at stand 3033. | |
| Company: | ProTecs |
| Booth: | Pennsylvania Pavilion Booth #1440 |
| Media Contact: | Christopher R. DiPaolo |
| Phone: | 610-941-1001 ext.380 |
| E-mail: | cdipaolo@protecsinc.com |
| Web: | www.protecsinc.com |
| ProTecs is a technically based professional services company providing program/project management, construction management, commissioning and integrated design/build services to emerging, small and mid-size biotechnology, pharmaceutical, medical device, healthcare, higher education and technology based companies. ProTecs was founded in 2005 to provide creative, value-driven approaches and entrepreneurial solutions to help companies bring their products to market in the most cost effective and timely manner. ProTecs aligns themselves with their clients' stated long-term strategic business objectives to meet their process, compliance, financial and time to market goals. | |
| Company: | Protein'eXpert |
| Booth: | 2057 - France Pavillion |
| Media Contact: | Christelle Dagoneau, Business Development Director |
| Phone: | 33 438 023 650 |
| E-mail: | marketing@proteinexpert.com |
| Web: | www.proteinexpert.com |
| Funded in 2000 in Grenoble, France, Protein'eXpert is an expanding CMO devoted to recombinant protein engineering & production for biomedical research applications. Our 36-staff company offers custom-designed services focusing on the discovery, optimisation and production of valuable target or therapeutic proteins. Since 2004, Protein'eXpert has extended its offering to the cGMP biomanufacturing of therapeutic protein products for early clinical trials via its integrated subsidiary PX'Pharma. The combination of Protein'eXpert and PX'Pharma know-how and manufacturing capacities allows ensuring a seamless transfer from therapeutic protein development up to clinical production stages. | |
| Company: | Proteologics |
| Media Contact: | Mrs. Anna Khazanov |
| Phone: | 972-8-9475666 |
| E-mail: | anna@proteologics.com |
| Web: | www.proteologics.com |
| Proteologics to present at the 2007 Business Forum. | |
| Proteologics is a leading force in translating the ubiquitin system into novel therapeutics. Drs. Avram Hershko and Aaron Ciechanover - the Nobel Prize laureates for the discovery of the ubiquitin system- chair the company's scientific advisory board. | |
| Proteologics' Rational Target & Drug Discovery Platform has already yielded several drug discovery programs, in antivirals, cancer and CNS. | |
| Proteologics is looking for strategic partners that like to benefit from Proteologics' unique expertise in target discovery, assay development & drug discovery in the ubiquitin system as well as in lead development and siRNA technology. | |
| Company: | Quincy Bioscience, LLC |
| Booth: | Wisconsin Pavilion |
| Media Contact: | Dakota Miller |
| Phone: | 608-233-2475 |
| E-mail: | dmiller@quincybioscience.com |
| Web: | www.quincybioscience.com |
| Quincy Bioscience is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat the diseases of aging. The company's therapeutic products focus on alleviating the consequences of impaired calcium homeostasis - the imbalance of calcium ions commonly thought to be related to neurodegenerative diseases such as Alzheimer's and Parkinson's. Quincy Bioscience is set apart by its cutting-edge applications of the calcium-binding protein aequorin, breaking new ground in the fight against age-related disease. Quincy Bioscience has also successfully developed the dietary supplement Prevagen (www.prevagen.com) and is launching this product on September 1, 2007. | |
| Company: | Qserve |
| Booth: | Hall C, stand 2633 |
| Media Contact: | W.W.M. Driessen |
| Phone: | 31 20 410 1250 |
| E-mail: | info@qservegroup.com |
| Web: | www.qservegroup.com |
| Qserve® is an independent medical device regulatory consulting firm with offices in the Netherlands and USA. Qserve has considerable in-house expertise in the areas of life science, medical device, biotechnology and regulatory compliance consulting, which include strategic approach, due diligence & GAP analysis, product compliance, pre-clinical, training, auditing and quality management systems implementation. | |
| Company: | Q Therapeutics, Inc. |
| Booth: | Utah Pavilion #2707 |
| Media Contact: | Deborah Eppstein |
| Phone: | 801-556-5004 |
| E-mail: | deppstein@qthera.com |
| Web: | www.qthera.com |
| Q Therapeutics has taken an innovative and practical approach to developing products to treat currently untreatable, debilitating diseases of the central nervous system. Q-Cells is a cell-based therapeutic that does naturally what no other drug can - it replaces the insulating myelin on damaged neurons and thus regenerates normal function of these neurons. Q-Cells are applicable to a wide range of demyelinating diseases, including MS, cerebral palsy, spinal cord injury and white matter stroke. | |
| Company: | Quebec Government |
| Booth: | 1020 |
| Phone: | 514 499-2199, ext. 3310 |
| E-mail: | nancy.carignan@mdeie.gouv.qc.ca |
| Web: | Mdeie.gouv.qc.ca/bio2007 |
| Discover the advantages of investing and doing business in Quebec, a world-leader in life sciences and stand a chance to win a free weekend at the Montreal International Jazz Festival. At Quebec Pavilion, booth 1020, meet specialists who will explain why your expansion projects should be carried out in Quebec. In private meeting rooms you will learn about fiscal incentives, financing, wage-competitive talent, etc. In Quebec we grow creativity and build on talent. www.mdeie.gouv.qc.ca/bio2007 | |
| Company: | Queensland Government |
| Booth: | Australia Pavilion (1515) |
| Media Contact: | Elouise Campion |
| Phone: | 61 7 3224 6784 |
| E-mail: | elouise.campion@ministerial.qld.gov.au |
| Web: | www.biotech.qld.gov.au |
| Beautiful weather, pristine beaches, relaxed lifestyle"¦combine these with our internationally renowned scientists, world class infrastructure, rich biodiversity and you have the perfect climate for biotechnology businesses. | |
| Company: | R5 Pharmaceuticals |
| Booth: | 1679 |
| Media Contact: | PAUL TITLEY |
| Phone: | 44 115 912 4410 |
| E-mail: | p.titley@r5pharma.com |
| Web: | www.r5pharma.com |
| R5 Pharmaceuticals is a contract service provider in drug development for the pharma and biotech industries. Based on the BioCity campus, Nottingham, R5 uses an efficient and integrated approach to pharmaceutical development, from drug formulation and delivery technology through to full scale manufacture. Led by a uniquely experienced management team, R5 Pharmaceuticals provides solutions for the development of safe and effective pharmaceutical materials to be used in clinical studies. The facilities include one of the very few cleanrooms in Europe, enabling the highest level of sterile product development. R5 is also applying its expertise to rapidly evolving areas such as paediatric products and nutraceuticals. | |
| Company: | Randox Laboratories |
| Booth: | 1881 |
| Media Contact: | Glenn Morton |
| Phone: | 44 (0) 28 9442 2413 |
| E-mail: | marketing@randox.com |
| Web: | www.randox.com |
| Randox Laboratories Ltd is a privately owned diagnostic reagent and equipment manufacturer and the leading British manufacturer of clinical chemistry reagents. Randox has 25 years experience in research, development, manufacture and marketing of high quality diagnostic reagents and equipment for laboratory medicine. The Randox portfolio includes Biochip Array Technology, clinical chemistry automation systems, external quality assurance schemes, internet driven QA systems, quality control materials, clinical reagents and environmental diagnostics. | |
| Company: | Raven biotechnologies, inc. |
| Media Contact: | Joseph Fisher |
| Phone: | 650-624-2656 |
| E-mail: | jmfisher@ravenbio.com |
| Web: | www.ravenbio.com |
| Raven biotechnologies, inc. is focused on the discovery of new drug targets for life-threatening conditions and the development of antibody products to treat them. Raven develops monoclonal antibody therapeutics, discovery tools, and technologies using unique, tissue-specific stem (i.e. progenitor) and tumor cells as antigens. Raven is currently focused on developing MAb therapies for cancer. The company's first clinical drug, RAV12, is a therapeutic antibody against a novel target present on GI cancers (pancreatic, stomach, and colon) as well as other adenocarcinomas. RAV12 is currently in a US multicenter Phase I Clinical Trial and will begin Phase II trials in mid-2007. | |
| Company: | Regeron, Inc. |
| Booth: | 2436 - Korea Pavilion |
| Media Contact: | Dahlkyun Oh, Ph.D. |
| Phone: | 82-33-258-6262 |
| E-mail: | dahlkyun@regeron.com |
| Web: | www.regeron.com |
| Regeron, Inc. - Strives for the healthy and productive long-life through innovative medicine that improves and even reverses natural and pathological manifestations of the old; Develops anti-aging biotech products-especially proteins for cosmetic and pharmaceutical industries. Currently on the market are hGH (human growth hormone) products for cosmetic purposes. Its long term goal is to develop an oral/pulmonary delivery system for protein drugs. | |
| Company: | Renewable Energy Group, Inc. |
| Booth: | Iowa Pavilion Booth 1356 |
| Media Contact: | Alicia Clancy |
| Phone: | 712-667-3418 |
| E-mail: | Alicia.clancy@regfuel.com |
| Web: | www.regfuel.com |
| Renewable Energy Group®, Inc. is the biodiesel industry leader of B100 sales and is the only full-service biodiesel company offering plant management, risk management, raw material procurement, plant construction, biodiesel production and biodiesel sales and marketing services. By 2008, REG's network of commercial scale biodiesel plants will have more than 200 million gallons of biodiesel available to the growing marketplace. | |
| Company: | Rentschler Biotechnologie GmbH |
| Booth: | 1055/1057 |
| Media Contact: | Friederike Braun |
| Phone: | 0049 7392 701 555 |
| E-mail: | biotech@rentschler.de |
| Web: | www.rentschler.de |
| Rentschler Biotechnologie is an independent, internationally operating service company that has been established in the field of biopharmaceuticals for over 30 years. | |
| With an all-inclusive package of integrated services, we can support you in all phases of product development. Our experienced staff develops your product through an integrated, custom tailored offer of biopharmaceutical services from the cell line to registration. | |
| GxP certified services: | |
| "¢Cell Line & Process Development | |
| "¢Production of Active Pharmaceutical Ingredients | |
| "¢Fill and Finish | |
| "¢Analytics & Quality Control | |
| "¢Regulatory Affairs & Quality Assurance | |
| "¢Corporate Project Management | |
| Company: | Restaino Bunbury & Associates Realtors |
| Booth: | Wisconsin Pavilion |
| Media Contact: | Bette McCarthy, CRP/GMS |
| Phone: | 608-833-7777 |
| E-mail: | mccarthy@restainobunbury.com |
| Web: | www.madisonrelocation.com |
| Full Service Relocation, Real Estate Firm. Delivering world class services such as Home-finding, Rental Assistance. Community Tours, Trailing Partner Program and much more!. Specializing in local and global relocations. A silver member and the preferred vendor for the Wisconsin Biotech and Medical Device Association. | |
| Company: | Rondaxe Pharma L.L.C. |
| Booth: | New York Pavilion, Booth 1833 |
| Media Contact: | Ann Kich |
| Phone: | 315 469-2800 ext 202 |
| E-mail: | akich@rondaxe.com |
| Web: | www.rondaxe.com |
| Rondaxe Pharma is a consulting firm that employs a diverse group of senior level staff from the pharmaceutical industry with expertise in chemical development, fermentation development, drug product development, supply chain strategy, analytical development, manufacturing operations, quality control, quality assurance, and regulatory affairs. Using our systematic approach, combined with depth and breadth of experience, Rondaxe's proactive strategies position our customers for success. Rondaxe's staff supports our clients with advice & council or will perform the work, providing full implementation and execution capabilities. By working with Rondaxe, our clients benefit by gaining one point of contact to the broader multi-disciplined team. | |
| Company: | SAGI |
| Booth: | 1408 |
| Media Contact: | Jacques-Henry VERGNE & Emmanuelle JOUANNET |
| Phone: | 33 1 40 75 33 04 |
| E-mail: | delehonte@sagi-immo.com |
| Web: | www.sagi-immo.com |
| Company: | San Francisco East Bay EDA |
| Booth: | 1569 |
| Media Contact: | Keith Sutton |
| Phone: | 510 272-3885 |
| E-mail: | keith@eastbayeda.org |
| Web: | www.eastbayeda.org |
| The East Bay - Bright Side of the San Francisco Bay: | |
| "¢UC Berkeley, the nation's #1 public undergraduate institution & graduate institution and 12 other colleges & universities | |
| "¢Large R&D cluster anchored by three national laboratories with combined budgets over $2 billion, and 13,000 employees | |
| "¢Silicon Valley's growth area | |
| "¢Over 35% of the Bay Area's land available for commercial development | |
| "¢Almost 40% of the Bay Area's future housing potential | |
| "¢The most robust & diversified economy in the Bay Area | |
| "¢One of the nation's fastest growing airports | |
| "¢The nation's 4th largest container seaport | |
| Company: | Shanghai ChemPartner Co., Ltd. |
| Booth: | 1633 |
| Phone: | 86-21-51320088 |
| E-mail: | sales@chempartner.com |
| Web: | http://www.chempartner.cn |
| Founded in 2003, Shanghai ChemPartner Co., Ltd.("ChemPartner") is a chemistry contract research company that provides customized services to international pharmaceutical, biotech and chemical companies. | |
| ChemPartner currently has a team of more than 400 chemists (by December 31, 2006), including more than 50 PhDs, who either had extensive R&D experiences with Pharmaceutical & Biotech companies and universities abroad, or were trained at the top chemistry research institutions in China. | |
| Company: | SIP Bio & Nano Technology Development Co.,Ltd. |
| Booth: | China Pavilion 06 |
| Phone: | 13701417264 |
| E-mail: | cheny@biobay.com.cn |
| Web: | www.biobay.com.cn |
| BioBay is the perfect location to start your career in the life-science field. This 213 acre R&D park is conveniently located in the China-Singapore Suzhou Industrial Park, Great Shanghai Area. We provide excellent quality facilities and services, with a first-class innovation environment, strong government support, a mature capital security system, a seed fund & Biopharma incubator, and professional public technical platforms and comprehensive service solutions. If you are interested in BioBay or would like more information, BioBay welcomes you to take a closer look. | |
| Company: | Solano Economic Development Corporation |
| Booth: | #1569 |
| Media Contact: | Earl Parker |
| Phone: | (208) 687-3075 |
| E-mail: | earlijoe@wildblue.net |
| Web: | www.solanoedc.org |
| Originally founded in 1983 and known as SEDCORP, the Solano Economic Development Corporation is a collaboration of private and public investors that provides a confidential leadership role for economic development marketing in Solano County and its seven cities: Benicia, Dixon, Fairfield, Rio Vista, Suisun City, Vacaville and Vallejo. | |
| The mission of the Solano Economic Development Corporation is to attract, grow, and retain business and industry in Solano County that enhance the economic vitality and quality of life in our communities. | |
| Company: | Southern Research Institute |
| Booth: | 1643 - Alabama Pavilion |
| Media Contact: | Rhonda Jung |
| Phone: | 205-581-2317/Cell: 205-337-9634 |
| E-mail: | Jung@sri.org |
| Web: | www.SouthernResearch.org |
| Southern Research is an independent not-for-profit center for scientific and contract research, known for innovative leadership in preclinical drug discovery and development, and environment and energy research. Clients include the National Institutes for Health, U.S. Departments of Defense and Energy; the EPA, NASA, and many major private and public pharmaceutical and biotech companies. Southern Research excels in preclinical studies of cancer, infectious diseases and emerging public health threats, CNS, and research into alternative energy sources. Scientists there have discovered six FDA-approved cancer drugs, with six additional drugs in the clinic, and evaluated almost 70% of all other FDA-approved cancer drugs on the market. | |
| Company: | Southside Bethlehem Keystone Innovation Zone |
| Booth: | Pennsylvania Pavilion |
| Media Contact: | Stephen Melnick |
| Phone: | (610) 266-7535 |
| E-mail: | smelnick@lehighvalley.org |
| Web: | www.lehighvalley.org (KIZ icon) |
| The Southside Bethlehem KIZ cultivates entrepreneurial opportunities, by aligning the resources of Lehigh University, and Northampton Community College with the existing business community. | |
| Our Technology Transfer Grant Program has provided over $250,000 in assistance to startup and early stage companies,enabling them to continue with their research and growth during critical times in their development. | |
| Our undergraduate internship program is designed to provide student internships in three distinct areas of concentration. Existing businesses, startup companies, agencies, and research centers. It is the intent of the Zone to create an awareness of the employment opportunities the "Life Sciences" may present within the KIZ. | |
| Company: | Southwest Research Institute |
| Booth: | 2520 |
| Media Contact: | Joe McDonough |
| Phone: | 210-522-4632 |
| E-mail: | Joe.mcdonough@swri.org |
| Web: | www.swri.org |
| SwRI offers synthesis, formulation, and analytical contract research services for all stages of the drug development process, from drug concept idea to clinical trials. Custom synthesis and medicinal chemistry services offer computational modeling capabilities, synthetic route design and execution (including medium to large-scale synthesis), and small-scale analog preparation. Contract services are available for large-scale API synthesis, pre-formulation development, spray drying and disk atomization. Other particle formation capabilities for microencapsulation-based, controlled-release drug delivery technologies for oral, injectable, implantable, nasal and transdermal platforms include GLP analytical and bioanalytical services, which include method development for pharmaceutical evaluation. SwRI has dedicated cGMP and cGLP facilities for clinical API and drug product preparation and evaluation. | |
| Company: | Springboard Atlantic Inc. |
| Booth: | 807 |
| Media Contact: | Tanya Moxley |
| Phone: | 902 421 5678 |
| E-mail: | info@springboardatlantic.ca |
| Web: | www.springboardatlantic.ca |
| Springboard Atlantic is a network of fourteen Atlantic Canadian universities with a mandate to increase the rate of commercialization of university research and development. Springboard makes connections to encourage the transfer of knowledge and technology to the private sector and therefore bring research to life. | |
| Springboard provides technology transfer resources to Atlantic universities so they can share services that would only be available at large institutions, providing equal opportunities to those big and small. | |
| Company: | SR Pharma plc / Atugen AG |
| Booth: | 668 |
| Ticker Symbol & Exchange: | SPA.L |
| Media Contact: | Thomas Christély |
| Phone: | 0049 30 9489 2800 |
| E-mail: | christely@atugen.com |
| Web: | www.srpharma.com / www.atugen.com |
| SR Pharma plc (new name: Silence-Therapeutics plc) is a European biopharmaceutical company, listed on AIM. SR Pharma is focused on RNAi therapeutics since mid 2005 when it acquired Atugen AG (Berlin) a world leader in RNAi therapeutics, a Nobel Prize winning technology that "silences" genes linked to the onset of disease. The Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi") and a proprietary delivery system ("AtuPLEX"). The Company has sublicensed one of its AtuRNAi compounds (RTP-801i) to Pfizer through its collaboration partner Quark Biotech Inc. This compound entered the clinic in early 2007. | |
| Company: | Staubach Company, The |
| Booth: | 1016 |
| Media Contact: | Liz Brazil |
| Phone: | 617-878-9200 |
| E-mail: | Liz.brazil@staubach.com |
| Web: | www.staubach.com |
| The Staubach Company is a leading global real estate advisory firm that delivers cost-effective solutions for the users of office, industrial and retail space. We have extensive experience in strategic consulting, site selection, acquisition, disposition, construction consulting / project management, real estate administration, portfolio management, financing and capital solutions. | |
| More than 1,400 people in 68 offices throughout North America represent Staubach's 2,850 clients. Staubach completed 6,750 transactions totaling $26 billion and 835 million square feet during the fiscal year ending June 2006. | |
| Worldwide, the DTZ Staubach Tie Leung partnership has more than 11,800 professionals delivering solutions to multinational clients. | |
| Company: | Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Booth: | 2676 |
| Media Contact: | Kathryn Holmes Johnson |
| Phone: | 301-908-8116 |
| E-mail: | kholmesj@skgf.com |
| Web: | www.skgf.com |
| Sterne Kessler Goldstein & Fox is an intellectual property (IP) law firm based in Washington, DC with a national/international client base. We have a biotechnology practice group focused on the specific IP needs of innovators in the biotech space. | |
| We are one of the premier IP firms in the world with expertise in the area of biotechnology, having practiced in the field for over twenty years. We prepare and prosecute patent applications before the U.S. and foreign patent offices, conduct interferences, oppositions, arbitrations, litigations (both as counsel and expert witnesses), advise worldwide biotechnological clients on intellectual property strategy, trade secrets, evaluation of patent portfolios, acquisitions, and employment agreements. | |
| Company: | Stricent AB |
| Booth: | 2065 |
| Media Contact: | Jerker Ringström |
| Phone: | 46 46 38 90 00 |
| E-mail: | info@stricent.com |
| Web: | www.stricent.com |
| Stricent provides products and services that support the drug development process. Our goal is to help biotech and pharmaceutical companies reduce the time, costs and risk of development. | |
| Combining our knowledge in drug development and regulatory structures with our proprietary digital process tools, we tailor solutions to meet each clientÂ's specific needs, whether it is a small biotech start-up or a large pharmaceutical entity. We know that a structured process is equally important for both. | |
| Company: | Suven Life Sciences Limited |
| Booth: | India Pavilion |
| Ticker Symbol & Exchange: | Suven, National Stock Exchange in India |
| Media Contact: | Mr. Venkatraman Sunder |
| Phone: | 91 40 6666 8666 |
| E-mail: | vsunder@act-india.com |
| Web: | www.act-india.com |
| ACT is a full spectrum Contract/Clinical Research Organization, part of Suven Life Sciences, composed of highly experienced professionals. Our meticulous planning process, expertise on different therapeutic areas and our relationship with investigators provide service offering with speed, efficiency and quality. Count on, be it regulatory affairs, site management, project management or data management with technology platform like Oracle Clinical will provide rewarding experience to our customers. And added to Suven's capabilities and new business model, Drug Discovery and Development Support Services (DDDSS), we offer seamless transition through every stage in drug development for global Pharma, Biotech and Medical device companies. | |
| Company: | Syntarga BV |
| Booth: | 2633 |
| Media Contact: | Dr. Vincent de Groot |
| Phone: | 31 24 3652878 |
| E-mail: | info@syntarga.com |
| Web: | www.syntarga.com |
| Syntarga B.V. is a biopharmaceutical company creating innovative chemistries to link potent cell-killing payloads to tumor-specific antibodies. The Company develops (combinations of) unique linker technologies and novel highly potent toxins. Syntarga generates ready-for-conjugation payloads yielding successful Antibody-Drug Conjugates (ADCs). | |
| Company: | Taiwan Liposome Company |
| Booth: | 2517 |
| Media Contact: | Ling-yao Lin |
| Phone: | 886-2-26557377 |
| E-mail: | info@tlcbio.com |
| Web: | www.tlcbio.com |
| TLC is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of major diseases and conditions, such as cancers, arterial diseases, ophthalmic conditions and fungal infections. TLC has a team of researchers, management, production experts, and advisers who are building TLC into an organization recognized for its excellence in targeted delivery and rapid advancement of products through the drug development process in South San Francisco, California and Taipei, Taiwan. The Company was chosen among Red Herring Asia Top 100 private companies in 2006. | |
| Company: | Tandem Labs |
| Booth: | 2707 |
| Media Contact: | Jean Pineault |
| Phone: | (609) 228-0201 |
| E-mail: | jean.pineault@tandemlabs.com |
| Web: | www.tandemlabs.com |
| Tandem Labs is a leading bioanalytical and immunoanalytical contract research organization (CRO) supporting pharmaceutical and biotechnology companies with their discovery, preclinical, and clinical drug development programs. Our laboratory menu includes advanced mass spectrometry, immunoanalytical support, pharmacokinetics, and pharmacodynamics. We also provide clinical research services through our strategic partners, Advanced Biomedical Research, Inc. (ABR) and Qualia Clinical Services. By combining scientific expertise, responsive communication, disciplined compliance, flexible service, and a commitment to information technology, Tandem Labs provides its clients with the data they need to confidently decide how to advance their programs. | |
| Company: | Translational Genomics Research Institute |
| Booth: | 2255 |
| Media Contact: | Galen P. Perry |
| Phone: | 602.343.8423 |
| E-mail: | gperry@tgen.org |
| Web: | www.tgen.org |
| The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, with a focus on developing earlier diagnoses and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen bases its research on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research. | |
| Company: | TSX Group |
| Booth: | 715 |
| Ticker Symbol & Exchange: | X |
| Media Contact: | Steve Kee |
| Phone: | 416-947-4682 |
| E-mail: | Steve.kee@tsx.com |
| Web: | www.tsx.com |
| TSX Group operates Canada's two national stock exchanges, Toronto Stock Exchange serving the senior equity market and TSX Venture Exchange serving the public venture equity market, Natural Gas Exchange (NGX), a leading North American exchange for the trading and clearing of natural gas and electricity contracts and Shorcan Brokers Limited, the country's first fixed income interdealer broker. TSX are the initials attached to the core equity operations of TSX Group (www.tsx.com): Toronto Stock Exchange, TSX Venture Exchange, TSX Markets, TSX Datalinx, and TSX Technologies. TSX Group is headquartered in Toronto and maintains offices in Montreal, Winnipeg, Calgary and Vancouver. | |
| Company: | UCB, Inc. |
| Media Contact: | Lisa Garman |
| Phone: | 770-970-7500 |
| E-mail: | Lisa.garman@ucb-group.com |
| Web: | www.ucb-group.com |
| UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing over 8,500 people in over 40 countries, UCB achieved revenues of € 2.5 billion in 2006. UCB is listed on the Euronext Brussels Exchange with a market capitalization of approximately € 6.0 billion. Worldwide headquarters are located in Brussels, Belgium, and U.S. headquarters are located in Atlanta, Georgia. | |
| Company: | UK Trade & Investment |
| Booth: | 1773 |
| Media Contact: | Joseph Pickerill |
| Phone: | 857-753-7887 |
| E-mail: | joseph.pickerill@fco.gov.uk or joepickerill@mycingular.blackberry.net |
| Web: | www.uktradeinvest.gov.uk |
| UK Trade & Investment is the lead government organisation that helps UK companies succeed in international markets and helps bring high quality investment into the UK. | |
| UK Trade & Investment welcomes the 60 plus UK companies and research organisations who are attending BIO 2007. | |
| This year at BIO, UK Trade & Investment will be unveiling a new drug pipeline which includes cutting-edge research which shows just how competitive UK's bio industry is. | |
| Come to the UK Trade & Investment stand at BIO, find out why the UK is number one for biotechnology in Europe. Or simply come and join our Boston Tea Party and enjoy a cup of British Tea! | |
| Company: | University of Nebraska Medical Center |
| Booth: | 2523 |
| Media Contact: | Vicky Cerino |
| Phone: | 402 350-0898 |
| E-mail: | vcerino@unmc.edu |
| Web: | www.unmc.edu |
| The University of Nebraska Medical Center will feature technologies, including a revolutionary recombinant protein purification technology. Allied Minds, a Boston-area pre-seed investment firm, purchased the license for the technology from UNeMed, the university's technology transfer company, formed Purtein LLC, and made a $500,000 investment. UNMC researchers also are working on a computer-aided orthopedic surgical system they hope will enable surgeons to do faster, less invasive, more precise bone cutting and alignment of knee implants. Biosecurity and biopreparedness innovations will be featured, including the country's only 10-bed patient biocontainment unit, laboratory data exchange, and antimicrobial drug discovery. | |
| Company: | United BioSource Corporation |
| Booth: | 2849 |
| Media Contact: | Tess Drahzal |
| Phone: | 240 644 0420 |
| E-mail: | info@unitedbiosource.com |
| Web: | www.unitedbiosource.com |
| UBC is a global pharmaceutical services organization that combines deep scientific knowledge with broad execution expertise across the lifecycle continuum. | |
| Our focus is on generating real-world data to support the development and commercialization of medical products for emerging and established life science companies. | |
| We partner with our clients to offer services in scientific research and strategic consulting, late stage development, registries and drug safety, data integration and analysis, clinical technologies, investigator services, patient programs, medical education, and market access services. | |
| UBC specializes in offering innovative ways to study drugs and devices with an emphasis on science, strategy, and execution. | |
| Company: | Van Eperen Public Relations |
| Booth: | 285 |
| Media Contact: | Laura Van Eperen |
| Phone: | 301.926.3394 |
| E-mail: | laurav@vepublicrelations.com |
| Web: | www.vepublicrelations.com |
| Van Eperen Public Relations (VE PR) is a full-service public relations and marketing firm serving clients around the globe. Located just outside of Washington, DC, the VE PR team of communications professionals works with domestic and international clients to help each positively showcase its products, services and people. For more information, go to www.vepublicrelations.com or call 1-301-926-3394. | |
| Company: | Vetter Pharma-Fertigung GmbH & Co. KG |
| Booth: | 961 |
| Media Contact: | Suzan Frohmann |
| Phone: | 0049-751-3700-0 |
| E-mail: | info@vetter-pharma.com |
| Web: | www.vetter-pharma.com |
| Vetter is a worldwide specialist in the aseptic production of FDA-approved pre-filled application systems. We support pharmaceutical and biotech customers from development to launch of new products. Our patented application systems give the customer a competitive edge in global markets. | |
| Company: | ViaLactia Biosciences (NZ) Limited |
| Booth: | 1711 - New Zealand Pavilion |
| Media Contact: | Ashvin Sood |
| Phone: | 64 21 685483 |
| E-mail: | ashvin.sood@vialactia.com |
| Web: | www.vialactia.com |
| ViaLactia is a biotechnology company operating as a fully owned subsidiary of Fonterra, the world's largest exporter of dairy products. ViaLactia's goals are the identification, discovery and commercialization of methods of selection of genes important to the dairy industry i.e. those affecting pasture grass performance, milk production & composition. ViaLactia's discoveries and technologies have applications to the biofuel sector. We have identified novel enzymes that facilitate the breakdown of plant cell walls into simpler sugars amenable for conventional fermentation. These enzymes are suitable for cellulosic ethanol production processes. They were discovered via a metagenomic approach exploring the bovine rumen. | |
| Company: | VioQuest Pharmaceuticals, Inc. |
| Booth: | 1226 |
| Ticker Symbol & Exchange: | VQPH.OB |
| Media Contact: | Brian Lenz |
| Phone: | 908-766-4400 |
| E-mail: | brian.lenz@vioquestpharm.com |
| Web: | www.vioquestpharm.com |
| VioQuest Pharmaceuticals focuses on acquiring, developing, and commercializing targeted therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in Phase I/IIa clinic trials: VQD-002 which inhibits activation of Akt; and Lenocta, an inhibitor of specific protein tyrosine phosphatases. VioQuest and the U.S. Army are planning to submit an NDA to the FDA in 2007 for Lenocta for the treatment of leishmaniasis. VioQuest recently in-licensed Xyfid a topical therapy for the treatment and prevention of Hand-Foot Syndrome, which is expected to enter Phase II trials in the second half of 2007. | |
| Company: | Viragen, Inc. |
| Booth: | Room E on 5/9/07 at 10:00 a.m. |
| Ticker Symbol & Exchange: | VRA - Amex |
| Media Contact: | Douglas W. Calder |
| Phone: | 954-233-8746 |
| E-mail: | dcalder@viragen.com |
| Web: | http://www.Viragen.com |
| Viragen is a bio-pharmaceutical company engaged in the research, development, manufacture and commercialization of therapeutic proteins for the treatment of cancers and viral diseases. Our product portfolio includes: Multiferon® (multi-subtype, human alpha interferon) which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, and other select cancers and infectious diseases; VG102, a novel monoclonal antibody that binds selectively to an antigen that is significantly over-expressed on nearly all malignant tumors; and VG106, a novel cytokine targeting difficult-to-treat cancers. We are also pioneering the development of The OVA System with the renowned Roslin Institute, creators of "Dolly the Sheep", as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies, by expressing these products in the egg whites of transgenic hens. | |
| Company: | VWR |
| Booth: | 533 (MBC Booth), 1300, 1301 (BIO Partners Pavilion Booth) |
| Phone: | 610-431-1700 |
| Web: | www.vwr.com |
| VWR is a leader in the global research laboratory industry and offers more than 1,200,000 products, from more than 2,500 manufacturers, to over 250,000 customers throughout North America and Europe. VWR's primary customers work in the pharmaceutical, life science, chemical, technology, food processing and consumer product industries. Affiliates operate in 20 countries and employ approximately 6,100 people. Its mission is to deliver excellence in the distribution of scientific supplies. | |
| For more information, phone 1-800-932-5000, visit www.vwr.com, or write, VWR International, Inc., 1310 Goshen Parkway, P.O. Box 2656, West Chester, PA 19380-0906. (VWR and design are trademarks of VWR International, Inc.) | |
| Company: | Waban Software, Inc. |
| Booth: | 2421 |
| Media Contact: | Pratap Malik, Ph.D. |
| Phone: | 617 899 8897 |
| E-mail: | pmalik@wabansoftware.com |
| Web: | www.wabansoftware.com |
| Waban Software provides 21CFR11 and HIPAA complaint software products and services for life-sciences information management. | |
| Waban SMS, Waban LIMS and Waban Explorer are for biological sample management, patient information management (de-identification & anonymization), pharmacogenomics & pharmacogenetics lab information management (LIMS) and for integration and analysis of biomarker, genomics, image and clinical data. | |
| Waban Explorer and Waban SCE are for managing the clinical trials data, analysis and reports and the complex business processes associated with the analysis and reporting process in a collaborative 21CFR11 compliant manner. Waban's products are integrated with all major statistical analysis tools and clinical data management systems. | |
| Company: | Wesley Research Institute, The |
| Booth: | Queensland Clinical Trials Network (QCTN) |
| Media Contact: | Colleen McMillan |
| Phone: | 61 7 3232 7264 |
| E-mail: | research@wesley.com.au |
| Web: | www.wesleyresearch.org.au |
| The Wesley Research Institute is an independent, not-for-profit organisation located in the grounds of The Wesley Hospital in Brisbane, which is part of one of Australia's largest private hospital groups. | |
| The Institute conducts research that focuses on improving patient care and quality of life. Our clinical and applied research aims to discover, test and refine new techniques for better diagnosis and treatment of illness and disease. | |
| The Wesley Research Institute's Clinical Trials Centre is a purpose-built and designed facility dedicated to conducting clinical trials that has access to one the most comprehensive range of private medical services in Australia. | |
| Company: | Western Australian Institute for Medical Research |
| Booth: | 1515 |
| Media Contact: | Natalie Papadopoulos |
| Phone: | 61 8 9388 9280 |
| E-mail: | natalie@capturemedia.com.au |
| Web: | www.waimr.uwa.edu.au |
| The Western Australian Institute for Medical Research is a one-stop-shop for your genomic, proteomic, microarray and antibody production needs. WAIMR will soon provide additional translational services to the global biotechnology and pharmaceutical industries with the completion of a custom built, 24 bed, early phase (I/II) clinical trial facility | |
| Company: | Whitehead Institute for Biomedical Research |
| Booth: | C39 |
| Media Contact: | Eric Bender |
| Phone: | 617-258-9183 |
| E-mail: | bender@wi.mit.edu |
| Web: | www.whitehead.mit.edu |
| Whitehead Institute is a biomedical research and education institution with pioneering programs in stem cells, cancer, immunology, regenerative biology, genetics and genomics. Wholly independent in its governance and research, Whitehead shares a teaching affiliation with Massachusetts Institute of Technology, where Whitehead's 15 faculty members hold joint appointments. At the leading edge of basic scientific research, Whitehead has over 190 patents under license to companies ranging in size from small local biotech firms to multinational pharmaceutical companies. | |
| Company: | Wilmer Cutler Pickering Hale and Dorr LLP |
| Booth: | Booth 552 |
| Media Contact: | Lauren G. Coppola |
| Phone: | (617) 526-6998 |
| E-mail: | lauren.coppola@wilmerhale.com |
| Web: | www.wilmerhale.com |
| WilmerHale is more than 1,100 lawyers strong, with offices in 11 cities across the globe. The firm offers unparalleled legal representation across a comprehensive range of practice areas that are critical to the success of our clients. We practice at the very top of the legal profession and offer a cutting-edge blend of capabilities that enables us to handle deals and cases of any size and complexity. WilmerHale has represented life sciences clients in boardrooms and courtrooms for four decades. As a result, we understand the business of our life sciences clients and the regulatory, competitive and consumer demands they confront. | |
| Company: | Women In Bio |
| Booth: | 2388 |
| Media Contact: | Ms. Robbie Melton |
| Phone: | 703-819-7647 |
| E-mail: | womeninbio@comcast.net |
| Web: | www.womeninbio.org |
| Women In Bio (WIB) is a vibrant organization dedicated to the success of women entrepreneurs, executives, scientists, students and professionals in the biotech and life sciences industry. WIB plans and presents unique and valuable educational programs that foster professional and personal growth for women having careers in the life sciences. Our innovative programs include: | |
| "¢education programs and workshops | |
| "¢networking events | |
| "¢professional development seminars | |
| "¢business opportunities for entrepreneurs and executives to meet investors, attorneys, accountants, marketing executives and human resource experts | |
| "¢programs on science and entrepreneurship for young women in middle and high school | |
| Company: | Worcester Polytechnic Institute/Gateway Park |
| Booth: | 533/C33 |
| Media Contact: | Christopher Hardwick |
| Phone: | 508-831-5874 |
| E-mail: | hardwick@wpi.edu |
| Web: | www.wpi.edu |
| Gateway Park, is an 11 acre, mixed-use destination with five life sciences buildings totaling 500,000 sq. ft. of adaptable lab space, loft condominiums and several retail establishments. It is situated in the 55-acre Gateway redevelopment district, comprised of numerous businesses, offices, and restaurants, as well as a Courtyard by Marriott hotel. | |
| WPI, a national research university, offers degrees in science, engineering, management, social sciences, and humanities. Its Life Sciences and Bioengineering Center, the first building at Gateway Park, opened in April 2007. The center serves as the focal point for life sciences and biotechnology graduate education and research at WPI. | |
| Company: | WXYZ Group |
| Booth: | 533/A18 |
| Media Contact: | Margarita Hunter |
| Phone: | 617-923-7600 |
| E-mail: | margarita.hunter@wolfelabs.com |
| Web: | www.wxyzgroup.com |
| The WXYZ Group includes Wolfe Laboratories, Xtal BioStructures, Y-Point BioAnalytical and Zenith BioVentures. These companies provide specialized research and development services to the biopharmaceutical industry, and partner with drug discovery organizations to overcome challenges and accelerate the growth of intellectual property. | |
| "¢Wolfe Laboratories - analytical, preformulation and formulation services. | |
| "¢Xtal BioStructures - structural characterization and structure-based drug design for drug targets and therapeutics using X-ray crystallography. | |
| "¢Y-Point BioAnalytical - LC/MS/MS-based bioanalytical and protein characterization services. | |
| "¢Zenith BioVentures - partners with discovery groups to provide early stage drug development on proprietary investigational therapeutics to address unmet needs in oncology and neurology. | |
| Company: | Xcellerex, Inc. |
| Booth: | 2381 |
| Media Contact: | David Monson |
| Phone: | 508-480-9235 x247 |
| E-mail: | dmonson@xcellerex.com |
| Web: | www.xcellerex.com |
| Xcellerex, a technology integration company, offers disposable technologies and top quality contract manufacturing services to the biopharmaceutical industry. Our management team has unique experience in drug development, taking biologics from preclinical development to FDA approval. | |
Xcellerex has created a new paradigm for building manufacturing systems in which process automation, fully disposable manufacturing components and portable modules (FlexFactory(TM)) are integrated to create alternatives to traditional stainless steel manufacturing facilities. | |
| Our "˜Try and Take' model provides maximum flexibility and cost effective manufacturing capabilities to our customers. We are committed to our customer's success in "˜speeding medicines to people' by providing them excellent services and technology. Call or email us for details. | |
| Company: | XOMA, Ltd. |
| Booth: | 2067 |
| Ticker Symbol & Exchange: | XOMA |
| Media Contact: | David Boyle |
| Phone: | 510-204-7234 |
| E-mail: | boyled@xoma.com |
| Web: | www.xoma.com |
| XOMA is a leader in the discovery, development and manufacturing of therapeutic monoclonal antibodies (mAbs). XOMA's mAb platform includes leading commercial antibody display phage libraries, hybridoma, Human Engineering, affinity maturation technologies. XOMA also has a fully integrated product development infrastructure, including cell line and process development, preclinical and clinical functions, and manufacturing. XOMA's pipeline includes both proprietary products and collaborative programs. XOMA receives royalties for RAPTIVA® and LUCENTIS®. Other strategic collaborations include Novartis International AG (formerly Chiron Corporation), Schering-Plough Corporation, Takeda Pharmaceutical Company Ltd. and Lexicon Genetics. XOMA has Human Engineering agreements with AVEO Pharmaceuticals, Inc. and Attenuon, LLC. | |
| Company: | ZENOAQ Nippon Zenyaku Kogyo Co., Ltd. |
| Booth: | 2757 Japan Pavilion |
| Media Contact: | Mr. SAZE KOUICHI / Mr. Yan Zhen |
| Phone: | 81-(0)24-945-2722 |
| E-mail: | zhen-yan@zenoaq.jp |
| Web: | http://www.zenoaq.jp |
ZENOAQ is a new name in cell storage reagent supply marketplace. However a company with 61 years history of corporate life and animal science based business behind it is anything but new. We have the production system complied with GMP and the R&D system in accordance with GLP standard. CELLBANKER is a brand name of cell freezing and thawing products of ZENOAQ, CELLBANKERs have serum type, serum replacement type and serum-free type. CELLBANKER do not need proguram freezer, cells suspended in CELLBANKER can be directly frozen in a deep freezer (-80 degree C). | |
| Company: | Zoomedia, Inc. |
| Booth: | California Pavilion, Booth Number 1465 |
| Media Contact: | Vanessa Silva, Director Client Services |
| Phone: | 415.474.1192 x250 |
| E-mail: | Vanessas@zoomedia.com |
| Web: | www.zoomedia.com |
| Founded in 1994, Zoomedia provides life science clients with a full range of communications and marketing services, from analysis through strategic planning, implementation, and production. We accelerate client success through intelligent communication initiatives that directly support business goals. By developing and implementing the right communication program at the right time, Zoomedia ensures that your company rises above the noise of what is an already crowded and fast growing market. | |
Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.
Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow@businesswire.com.
© 2007 Business Wire
